NI,YONG,倪永,PARIKH,BHAVNISH,帕瑞克巴哈辛许,帕瑞克巴哈辛許,YELESWARAM,KRISHNASWAMY,伊勒史汪克里施奈斯瓦米,ERICKSON-VIITANEN,SUSAN,艾力克森－维他南苏珊,艾力克森－維他南蘇珊,WILLIAMS,WILLIAM V.,威帘斯威帘 W,威簾斯威簾 W
申请号：
TW107133083
公开号：
TW201922255A
申请日:
2013.11.14
申请国别(地区):
TW
年份:
2019
代理人:
摘要：
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.本發明涉及盧梭利替尼或其藥學上可接受的鹽之緩釋性調配物和劑型，它們可用於治療傑納斯激酶相關疾病，如骨髓增生性病症。
